Routine digital examination explores only 8 cm. of the colon. Sigmoidoscopy reveals an additional 17 cm. But colorectal cancer can occur throughout the colon. And it's often asymptomatic.

That's why the 'Hemoccult' guaiac method is so valuable as a preliminary diagnostic screen. 'Hemoccult' is a reliable detector of blood throughout the colon. In addition, it's accurate, inexpensive, simple to use and easy to read. The test can be done in your office in minutes, or given to your patient to take home and return by mail.

More than 100,000 cases of colorectal cancer will occur in the United States this year. The earlier they are diagnosed, the greater the chances for successful treatment. Send for your free 'Hemoccult' starter package, today.

'Hemoccult' is available through local distributors, nationwide.
Notice to Members of the American Association for Cancer Research

Officers for 1979-1980
President: Paul P. Carbone, Wisconsin Clinical Cancer Center, 1300 University Avenue, Madison, Wisconsin 53706
Vice President: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021
Secretary-Treasurer: Frederick S. Philips, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021

Annual Dues
The annual dues of active members of the American Association for Cancer Research are $35.00 and they include a subscription to the journal Cancer Research. The regular subscription price of Cancer Research for members of the Association is $25.00 per annual volume. Payment of dues and changes of address of members of the Association should be sent promptly to Dr. Frederick S. Philips.

Sponsors
Cancer Research is sponsored by the American Association for Cancer Research, Inc.; the National Cancer Institute, United States Public Health Service; the American Cancer Society, Inc.; the Damon Runyon-Walter Winchell Cancer Fund; and the Elsa U. Pardee Foundation; publication costs are met in part by grants from the same agencies.

Subscription Information
Cancer Research is published monthly, one volume per year, for Cancer Research, Inc. by Waverly Press, Inc., 428 E. Preston Street, Baltimore, Maryland 21202. Subscriptions include the Proceedings of the American Association for Cancer Research and the American Society of Clinical Oncology, issued in March of each year. Except for members of the American Association for Cancer Research, all subscriptions are payable in advance to the publisher of the journal, Waverly Press, Inc., to which all business communications, remittances (in United States currency or its equivalent), and subscription orders should be sent. Nonmembers of the American Association for Cancer Research may subscribe to the journal Cancer Research at the rate of $100.00 per annual volume, including postage. The publisher should be notified of changes of address 60 days in advance; subscribers should give both their old and new addresses. Members of the American Association for Cancer Research should also inform the Secretary-Treasurer, Dr. Frederick S. Philips, of their change of address. Copies of the journal which are undeliverable because of address changes will be destroyed.

Back Issues and Single Copy Sales of the Journal
Copies of back stock of the journal Cancer Research for the two years preceding the current year may be ordered from Waverly Press, Inc. As long as supplies permit, single copies of Cancer Research will be sold by this company at $15.00 per copy for regular issues and $15.00 per copy for Part 2 issues which contain material from conferences on topics related to cancer. The annual Proceedings of the American Association for Cancer Research and the American Society of Clinical Oncology is available at $10.00 per copy. When available, earlier issues may be obtained from Walter J. Johnson, Inc., 355 Chestnut Street, Norwood, New Jersey 07648.

Advertisements in Cancer Research
Advertisement insertion orders and copy must be received 60 days prior to the month of issue in which the advertisement is to be published. The journal is mailed on or about the 20th of the month preceding the month of issue. Inquiries about advertising should be directed to: Donald H. Nichols, Vice President, Journal Sales, Waverly Press, Inc., 428 E. Preston Street, Baltimore, Maryland 21202. Telephone: 301/526-4280.

Submission of Manuscripts
Papers submitted for publication in Cancer Research and all other communications for the attention of the Editor should be sent to: Dr. Peter N. Magee, Editor, Cancer Research, Fels Research Institute, Temple University School of Medicine, Philadelphia, Pennsylvania 19140. Telephone: 215/287-4210. Cancer Research publishes original clinical, experimental or statistical studies in the fields of cancer research and cancer-related biomedical science. Authors should consult the detailed "Instructions for Authors" printed in the January issue of the journal, copies of which are available upon request.

Manuscript Processing Fee
Journal policy requires that a single manuscript processing fee of $50.00 be assessed for all papers to defray the expenses incurred in the editorial review process. An invoice is sent to the author upon receipt of the manuscript. Review to determine acceptability will not be delayed pending payment of this fee.

Copyright and Copyright Clearance Center
The Copyright Revision Act (PL 94-553), which became effective January 1, 1978, states that the copyright of a work is vested in the author from the moment of creation of the work, and all authors who wish to publish in Cancer Research must formally transfer copyright to the proprietor of the journal, Cancer Research, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepare their articles as part of their official duties as employees of the U. S. Federal Government are not required to transfer copyright to Cancer Research, Inc., since these articles are considered to be in the public domain. However, it is necessary for these authors to sign the appropriate section of the transfer form. In the case of articles supported by federal grants or contracts, copyright transfer to Cancer Research, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

The duly authorized agent of a commercial firm or commissioning organization must sign the transfer form if the author prepared the article as part of his or her official duties as an employee.

Appropriate forms for transfer of copyright will be sent routinely with acknowledgment of receipt of manuscripts for review. They may also be requested from the Cancer Research Editorial Office. The journal will not publish a paper unless the form is properly completed and signed.

The appearance of the code 0008-5472/80/0040-0000$02.00 at the top of the first page of an article in Cancer Research indicates that the copyright owner has consented that copies of the article may be made for personal or internal use, provided that the copier pay the stated per-copy fee of $2.00 through the Copyright Clearance Center, Inc. This Center is a nonprofit organization through which individuals and institutions may reimburse a copyright owner for photocopying journal articles beyond what is defined as "fair use" in Sections 107 and 108 of the Copyright Revision Act of 1978. Those who wish to photocopy Cancer Research articles may report the number of copies they have made together with the fee code to: Copyright Clearance Center, Inc., Operations Office, P. O. Box 765, Schenectady, New York 12301. Remittances may be sent to the Center at the time of reporting or the Center will bill the user on a monthly basis. Deposit accounts and prepayment plans may also be arranged.

Articles from any issue of Cancer Research dating from 1973 may be photocopied under the same conditions and at the same fee. If there is no fee code, as in issues prior to June 1978, the user should report the title of the journal, the month and the year of the issue, and the initial page number of the article, together with a statement of the number of copies made. If an article published after June 1978 does not carry a fee code, it is understood to be in the public domain and may be copied without restriction or payment of a fee.

Cancer Research is abstracted or indexed in Biological Abstracts, Chemical Abstracts, Index Medicus, Science Citation Index, and by the International Cancer Research Data Bank.

No responsibility is accepted by the Editors, by Cancer Research, Inc., by the American Association for Cancer Research, Inc., or by the publisher of the journal Cancer Research for the opinions expressed by contributors or for the content of the advertisements.

Cancer Research (ISSN 0008-5472) is published monthly for $25 per year (for members of the American Association for Cancer Research) or $100 per year (for nonmembers) by Waverly Press, Inc., 428 E. Preston Street, Baltimore, Md. 21202. Second-class postage paid at Baltimore, Md. and additional mailing offices.

POSTMASTER: Send address changes to Cancer Research, c/o Waverly Press, Inc., 428 E. Preston Street, Baltimore, Md. 21202.

Copyright 1980 by Cancer Research, Inc.
Oncology

Following a phase of extreme specialization, experimental and clinical cancer research is now undergoing a process of consolidation. Nonetheless, the advances contributed at so many basic levels remain remote from direct medical application. Through its editorial policy and the quality of its contributions, Oncology has functioned to accelerate the consolidation of work in this field. In each issue, findings from basic research are integrated with current theoretic knowledge and discussed in terms of their relevance to the detection and treatment of cancer. The importance of the journal's distinct function has been reflected as a steady growth in the number of readers.

Vol. 36, No. 5, 1979


Carruthers, C.; Baumier, A., and Lin, J.K. (Buffalo, N.Y./Taipei): Detection by Antihapten Antibodies of Liver-Bound Compounds Related to Azocarcinogens or Their Metabolites

Grubbs, B.; Rogers, W., and Cameron, I. (San Antonio, Tex.): Total Parenteral Nutrition and Inhibition of Glucosoneogenesis on Tumor-Host Responses

Tebbi, K.; Gross, S., and Newman, A.J. (Cleveland, Ohio): Increased Colony-Stimulating Activity in the Plasma of a Patient with Lymphoproliferative Metastatic to the Liver

Májyk, A.; Abrahámová, J.; Kořinková, P., and Bek, V. (Prague): HLA System and Testicular Germinative Tumors

Němec, J.; Zamrazil, V.; Pohnková, D.; Zeman, V., and Rohling, S. (Prague): Mode of Spread of Thyroid Cancer

Lokich, J.J.; Garnick, M.B., and Legg, M. (Boston, Mass.): Intraluminal Immune Therapy. Methanol Extraction Residue of BCG or Purified Protein Derivative

Capel, I.D.; Jenner, M.; Pinnock, M.H.; Dorrell, H.M.; Payne, D.C., and Williams, D.C. (Oxted): Correlation between Tumour Size, Metastatic Spread and Galactosyl Transferase Activity in Cyclophosphamide-Treated Mice Bearing the Lewis Lung Carcinoma